Chaitra S. Ujjani, MD
Novel regimens recently added to the paradigms of Hodgkin lymphoma and mantle cell lymphoma (MCL) have led to a more personalized therapeutic approach in clinical practice, explained Chaitra S. Ujjani, MD.
State of the Science Summit™ on Hematologic Malignancies, Ujjani discussed the latest progress in both Hodgkin lymphoma and MCL.
OncLive®: Please provide an overview of the ECHELON-1 study.
: This is a frontline classical Hodgkin lymphoma study for advanced-stage patients. In this study, they looked at standard ABVD chemotherapy compared with AVD plus brentuximab. We know that in patients with previously untreated Hodgkin lymphoma, up to 40% of them will be refractory or will relapse to their initial therapy. Therefore, better induction regimens are necessary.
This led to the approval of brentuximab. The other thing to take away is that there are some toxicities to manage; neuropathy can be an issue. This can be managed with dose adjustment. Febrile neutropenia also frequently comes up.
Are there any unanswered questions with brentuximab vedotin?
There are a few different things that still need to be explored. A group [of researchers] at Dana-Farber Cancer Institute published a study of brentuximab vedotin in combination with bendamustine for relapsed patients. They had achieved complete remission under that regimen, allowing them to be eligible for a stem cell transplant. That's an interesting combination.
... to read the full story